For best viewing of the website please use Mozilla Firefox or Google Chrome.
Citation: Tiandan Xiang, Junzhong Wang, Xin Zheng. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages [J].VIROLOGICA SINICA, 2022, 37(6) : 786-795.  http://dx.doi.org/10.1016/j.virs.2022.11.007

The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages

  • Corresponding author: Xin Zheng, xinz@hust.edu.cn
  • Received Date: 01 August 2022
    Accepted Date: 18 November 2022
    Available online: 23 November 2022
  • The recently discovered SARS-CoV-2 variant Omicron (B.1.1.529) has rapidly become a global public health issue. The substantial mutations in the spike protein in this new variant have raised concerns about its ability to escape from pre-existing immunity established by natural infection or vaccination. In this review, we give a summary of current knowledge concerning the antibody evasion properties of Omicron and its subvariants (BA.2, BA.2.12.1, BA.4/5, and BA.2.75) from therapeutic monoclonal antibodies and the sera of SARS-CoV-2 vaccine recipients or convalescent patients. We also summarize whether vaccine-induced cellular immunity (memory B cell and T cell response) can recognize Omicron specifically. In brief, the Omicron variants demonstrated remarkable antibody evasion, with even more striking antibody escape seen in the Omicron BA.4 and BA.5 sub-lineages. Luckily, the third booster vaccine dose significantly increased the neutralizing antibodies titers, and the vaccine-induced cellular response remains conserved and provides second-line defense against the Omicron.

  • 加载中
    1. Ai, J., Wang, X., He, X., Zhao, X., Zhang, Y., Jiang, Y., Li, M., Cui, Y., Chen, Y., Qiao, R., Li, L., Yang, L., Li, Y., Hu, Z., Zhang, W., Wang, P., 2022. Antibody evasion of SARSCoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe 30, 1077-1083.

    2. Arbel, R., Sergienko, R., Friger, M., Peretz, A., Beckenstein, T., Yaron, S., Netzer, D., Hammerman, A., 2022. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat. Med. 28, 1486-1490.

    3. Barda, N., Dagan, N., Cohen, C., Hernán, M.A., Lipsitch, M., Kohane, I.S., Reis, B.Y., Balicer, R.D., 2021. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 398, 2093-2100.

    4. Beheshti, N.A., Keikha, M., 2022. BA.2.12.1 is a new omicron offshoot that is a highly contagious but not severe disease. Ann Med Surg (Lond). 79, 104034.

    5. Callaway, E., 2021. Heavily mutated Omicron variant puts scientists on alert. Nature 600, 21.

    6. Cameroni, E., Bowen, J.E., Rosen, L.E., Saliba, C., Zepeda, S.K., Culap, K., Pinto, D., VanBlargan, L.A., De Marco, A., di Iulio, J., Zatta, F., Kaiser, H., Noack, J., Farhat, N., Czudnochowski, N., Havenar-Daughton, C., Sprouse, K.R., Dillen, J.R., Powell, A.E., Chen, A., Maher, C., Yin, L., Sun, D., Soriaga, L., Bassi, J., Silacci-Fregni, C., Gustafsson, C., Franko, N.M., Logue, J., Iqbal, N.T., Mazzitelli, I., Geffner, J., Grifantini, R., Chu, H., Gori, A., Riva, A., Giannini, O., Ceschi, A., Ferrari, P., Cippà, P.E., Franzetti-Pellanda, A., Garzoni, C., Halfmann, P.J., Kawaoka, Y., Hebner, C., Purcell, L.A., Piccoli, L., Pizzuto, M.S., Walls, A.C., Diamond, M.S., Telenti, A., Virgin, H.W., Lanzavecchia, A., Snell, G., Veesler, D., Corti, D., 2022. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664-670.

    7. Cao, Y., Song, W., Wang, L., Liu, P., Yue, C., Jian, F., Yu, Y., Yisimayi, A., Wang, P., Wang, Y., Zhu, Q., Deng, J., Fu, W., Yu, L., Zhang, N., Wang, J., Xiao, T., An, R., Wang, J., Liu, L., Yang, S., Niu, X., Gu, Q., Shao, F., Hao, X., Jin, R., Wang, Y., Xie, X.S., Wang, X., 2022a. Characterizations of enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host Microbe 30, 1527-1539.

    8. Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., Wang, J., Wang, Y., Niu, X., Yang, S., Liang, H., Sun, H., Li, T., Yu, Y., Cui, Q., Liu, S., Yang, X., Du, S., Zhang, Z., Hao, X., Shao, F., Jin, R., Wang, X., Xiao, J., Wang, Y., Xie, X.S., 2022b. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657-663.

    9. Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., Yu, Y., Wang, P., Zhang, Z., Liu, P., An, R., Hao, X., Wang, Y., Wang, J., Feng, R., Sun, H., Zhao, L., Zhang, W., Zhao, D., Zheng, J., Yu, L., Li, C., Zhang, N., Wang, R., Niu, X., Yang, S., Song, X., Chai, Y., Hu, Y., Shi, Y., Zheng, L., Li, Z., Gu, Q., Shao, F., Huang, W., Jin, R., Shen, Z., Wang, Y., Wang, X., Xiao, J., Xie, X.S., 2022c. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593-602.

    10. Carreño, J.M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A.J., Kawabata, H., Sominsky, L.A., Clark, J.J., Adelsberg, D.C., Bielak, D.A., Gonzalez-Reiche, A.S., Dambrauskas, N., Vigdorovich, V., Alburquerque, B., Amoako, A.A., Banu, R., Beach, K.F., Bermúdez-González, M.C., Cai, G.Y., Ceglia, I., Cognigni, C., Farrugia, K., Gleason, C.R., van de Guchte, A., Kleiner, G., Khalil, Z., Lyttle, N., Mendez, W.A., Mulder, L.C.F., Oostenink, A., Rooker, A., Salimbangon, A.T., Saksena, M., PanizMondolfi, A.E., Polanco, J., Srivastava, K., Sather, D.N., Sordillo, E.M., Bajic, G., van Bakel, H., Simon, V., Krammer, F., 2022. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682-688.

    11. Chandrashekar, A., Yu, J., McMahan, K., Jacob-Dolan, C., Liu, J., He, X., Hope, D., Anioke, T., Barrett, J., Chung, B., Hachmann, N.P., Lifton, M., Miller, J., Powers, O., Sciacca, M., Sellers, D., Siamatu, M., Surve, N., VanWyk, H., Wan, H., Wu, C., Pessaint, L., Valentin, D., Van Ry, A., Muench, J., Boursiquot, M., Cook, A., Velasco, J., Teow, E., Boon, A., Suthar, M.S., Jain, N., Martinot, A.J., Lewis, M.G., Andersen, H., Barouch, D.H., 2022. Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell 185, 1549-1555.

    12. Cheng, S.M.S., Mok, C.K.P., Leung, Y.W.Y., Ng, S.S., Chan, K.C.K., Ko, F.W., Chen, C., Yiu, K., Lam, B.H.S., Lau, E.H.Y., Chan, K.K.P., Luk, L.L.H., Li, J.K.C., Tsang, L.C.H., Poon, L.L.M., Hui, D.S.C., Peiris, M., 2022. Neutralizing antibodies against the SARSCoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat. Med. 28, 486-489.

    13. Choi, S.J., Kim, D., Noh, J.Y., Kim, S., Park, S., Jeong, H.W., Shin, E., 2022. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant. Cell. Mol.Immunol. 19, 447-448.

    14. Costa Clemens, S.A., Weckx, L., Clemens, R., Almeida Mendes, A.V., Ramos Souza, A., Silveira, M.B.V., Da Guarda, S.N.F., de Nobrega, M.M., de Moraes Pinto, M.I., Gonzalez, I.G.S., Salvador, N., Franco, M.M., de Avila Mendonça, R.N., Queiroz Oliveira, I.S., de Freitas Souza, B.S., Fraga, M., Aley, P., Bibi, S., Cantrell, L., Dejnirattisai, W., Liu, X., Mongkolsapaya, J., Supasa, P., Screaton, G.R., Lambe, T., Voysey, M., Pollard, A.J., Bittaye, M., Woods, D., Davies, S., Smith, H., Ulaszewska, M., Sanders, H., Mabette, R., Vernon, S., Valliji, Z., Mead, G., Tejpal, C., Park, J., Beveridge, A., Eldawi, A., Felle, S., Fraga, M., Muniz Martins, T., Martins Medrado, C.L., de Arruda Cordeiro Matos, L.J., 2022. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399, 521-529.

    15. Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., Yang, M., Xu, G., Zhu, B., Fu, W., Chu, T., Feng, L., Wang, Y., Pei, X., Yang, P., Xie, X.S., Cao, L., Cao, Y., Wang, X., 2022. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell 185, 860-871.

    16. Davies, M.A., Morden, E., Rosseau, P., Arendse, J., Bam, J.L., Boloko, L., Cloete, K., Cohen, C., Chetty, N., Dane, P., Heekes, A., Hsiao, N.Y., Hunter, M., Hussey, H., Jacobs, T., Jassat, W., Kariem, S., Kassanjee, R., Laenen, I., Le Roux, S., Lessells, R., Mahomed, H., Maughan, D., Meintjes, G., Mendelson, M., Mnguni, A., Moodley, M., Murie, K., Naude, J., Ntusi, N., Paleker, M., Parker, A., Pienaar, D., Preiser, W., Prozesky, H., Raubenheimer, P., Rossouw, L., Schrueder, N., Smith, B., Smith, M., Solomon, W., Symons, G., Taljaard, J., Wasserman, S., Wilkinson, R.J., Wolmarans, M., Wolter, N., Boulle, A., 2022. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa. Int J Infect Dis. S1201-9712(22)00615-4.

    17. Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H.M.E., Ginn, H.M., Mentzer, A.J., Tuekprakhon, A., Nutalai, R., Wang, B., Dijokaite, A., Khan, S., Avinoam, O., Bahar, M., Skelly, D., Adele, S., Johnson, S.A., Amini, A., Ritter, T.G., Mason, C., Dold, C., Pan, D., Assadi, S., Bellass, A., Omo-Dare, N., Koeckerling, D., Flaxman, A., Jenkin, D., Aley, P.K., Voysey, M., Costa Clemens, S.A., Naveca, F.G., Nascimento, V., Nascimento, F., Fernandes Da Costa, C., Resende, P.C., Pauvolid-Correa, A., Siqueira, M.M., Baillie, V., Serafin, N., Kwatra, G., Da Silva, K., Madhi, S.A., Nunes, M.C., Malik, T., Openshaw, P.J.M., Baillie, J.K., Semple, M.G., Townsend, A.R., Huang, K.A., Tan, T.K., Carroll, M.W., Klenerman, P., Barnes, E., Dunachie, S.J., Constantinides, B., Webster, H., Crook, D., Pollard, A.J., Lambe, T., Paterson, N.G., Williams, M.A., Hall, D.R., Fry, E.E., Mongkolsapaya, J., Ren, J., Schreiber, G., Stuart, D.I., Screaton, G.R., Conlon, C., Deeks, A.S., Frater, J., Frending, L., Gardiner, S., Jämsén, A., Jeffery, K., Malone, T., Phillips, E., Rothwell, L., Stafford, L., Baillie, J.K., Semple, M.G., Openshaw, P.J., Carson, G., Alex, B., Andrikopoulos, P., Bach, B., Barclay, W.S., Bogaert, D., Chand, M., Chechi, K., Cooke, G.S., Da Silva Filipe, A., de Silva, T., Docherty, A.B., Dos Santos Correia, G., Dumas, M., Dunning, J., Fletcher, T., Green, C.A., Greenhalf, W., Griffin, J.L., Gupta, R.K., Harrison, E.M., Hiscox, J.A., Wai Ho, A.Y., Horby, P.W., Ijaz, S., Khoo, S., Klenerman, P., Law, A., Lewis, M.R., Liggi, S., Lim, W.S., Maslen, L., Mentzer, A.J., Merson, L., Meynert, A.M., Moore, S.C., Noursadeghi, M., Olanipekun, M., Osagie, A., Palmarini, M., Palmieri, C., Paxton, W.A., Pollakis, G., Price, N., Rambaut, A., Robertson, D.L., Russell, C.D., Sancho-Shimizu, V., Sands, C.J., Scott, J.T., Sigfrid, L., Solomon, T., Sriskandan, S., Stuart, D., Summers, C., Swann, O.V., Takats, Z., Takis, P., Tedder, R.S., Thompson, A.R., Thomson, E.C., Thwaites, R.S., Turtle, L.C., Zambon, M., Hardwick, H., Donohue, C., Griffiths, F., Oosthuyzen, W., Donegan, C., Spencer, R.G., Norman, L., Pius, R., Drake, T.M., Fairfield, C.J., Knight, S.R., Mclean, K.A., Murphy, D., Shaw, C.A., Dalton, J., Girvan, M., Saviciute, E., Roberts, S., Harrison, J., Marsh, L., Connor, M., Halpin, S., Jackson, C., Gamble, C., Plotkin, D., Lee, J., Leeming, G., Law, A., Wham, M., Clohisey, S., Hendry, R., Scott-Brown, J., Shaw, V., McDonald, S.E., Keating, S., Ahmed, K.A., Armstrong, J.A., Ashworth, M., Asiimwe, I.G., Bakshi, S., Barlow, S.L., Booth, L., Brennan, B., Bullock, K., Catterall, B.W., Clark, J.J., Clarke, E.A., Cole, S., Cooper, L., Cox, H., Davis, C., Dincarslan, O., Dunn, C., Dyer, P., Elliott, A., Evans, A., Finch, L., Fisher, L.W., Foster, T., Garcia-Dorival, I., Gunning, P., Hartley, C., Jensen, R.L., Jones, C.B., Jones, T.R., Khandaker, S., King, K., Kiy, R.T., Koukorava, C., Lake, A., Lant, S., Latawiec, D., Lavelle-Langham, L., Lefteri, D., Lett, L., Livoti, L.A., Mancini, M., McDonald, S., McEvoy, L., McLauchlan, J., Metelmann, S., Miah, N.S., Middleton, J., Mitchell, J., Moore, S.C., Murphy, E.G., Penrice-Randal, R., Pilgrim, J., Prince, T., Reynolds, W., Ridley, P.M., Sales, D., Shaw, V.E., Shears, R.K., Small, B., Subramaniam, K.S., Szemiel, A., Taggart, A., Tanianis-Hughes, J., Thomas, J., Trochu, E., van Tonder, L., Wilcock, E., Zhang, J.E., Flaherty, L., Maziere, N., Cass, E., Carracedo, A.D., Carlucci, N., Holmes, A., Massey, H., Murphy, L., McCafferty, S., Clark, R., Fawkes, A., Morrice, K., Maclean, A., Wrobel, N., Donnelly, L., Coutts, A., Hafezi, K., MacGillivray, L., Gilchrist, T., Adeniji, K., Agranoff, D., Agwuh, K., Ail, D., Aldera, E.L., Alegria, A., Allen, S., Angus, B., Ashish, A., Atkinson, D., Bari, S., Barlow, G., Barnass, S., Barrett, N., Bassford, C., Basude, S., Baxter, D., Beadsworth, M., Bernatoniene, J., Berridge, J., Berry, C., Best, N., Bothma, P., Chadwick, D., Brittain-Long, R., Bulteel, N., Burden, T., Burtenshaw, A., Caruth, V., Chadwick, D., Chambler, D., Chee, N., Child, J., Chukkambotla, S., Clark, T., Collini, P., Cosgrove, C., Cupitt, J., Cutino-Moguel, M., Dark, P., Dawson, C., Dervisevic, S., Donnison, P., Douthwaite, S., Drummond, A., DuRand, I., Dushianthan, A., Dyer, T., Evans, C., Eziefula, C., Fegan, C., Finn, A., Fullerton, D., Garg, S., Garg, S., Garg, A., Gkrania-Klotsas, E., Godden, J., Goldsmith, A., Graham, C., Hardy, E., Hartshorn, S., Harvey, D., Havalda, P., Hawcutt, D.B., Hobrok, M., Hodgson, L., Hormis, A., Jacobs, M., Jain, S., Jennings, P., Kaliappan, A., Kasipandian, V., Kegg, S., Kelsey, M., Kendall, J., Kerrison, C., Kerslake, I., Koch, O., Koduri, G., Koshy, G., Laha, S., Laird, S., Larkin, S., Leiner, T., Lillie, P., Limb, J., Linnett, V., Little, J., Lyttle, M., MacMahon, M., MacNaughton, E., Mankregod, R., Masson, H., Matovu, E., McCullough, K., McEwen, R., Meda, M., Mills, G., Minton, J., Mirfenderesky, M., Mohandas, K., Mok, Q., Moon, J., Moore, E., Morgan, P., Morris, C., Mortimore, K., Moses, S., Mpenge, M., Mulla, R., Murphy, M., Nagel, M., Nagarajan, T., Nelson, M., Norris, L., O Shea, M.K., Otahal, I., Ostermann, M., Pais, M., Palmieri, C., Panchatsharam, S., Papakonstantinou, D., Paraiso, H., Patel, B., Pattison, N., Pepperell, J., Peters, M., Phull, M., Pintus, S., Pooni, J.S., Planche, T., Post, F., Price, D., Prout, R., Rae, N., Reschreiter, H., Reynolds, T., Richardson, N., Roberts, M., Roberts, D., Rose, A., Rousseau, G., Ruge, B., Ryan, B., Saluja, T., Schmid, M.L., Shah, A., Shanmuga, P., Sharma, A., Shawcross, A., Sizer, J., Shankar-Hari, M., Smith, R., Snelson, C., Spittle, N., Staines, N., Stambach, T., Stewart, R., Subudhi, P., Szakmany, T., Tatham, K., Thomas, J., Thompson, C., Thompson, R., Tridente, A., Tupper-Carey, D., Twagira, M., Vallotton, N., Vancheeswaran, R., Vincent-Smith, L., Visuvanathan, S., Vuylsteke, A., Waddy, S., Wake, R., Walden, A., Welters, I., Whitehouse, T., Whittaker, P., Whittington, A., Papineni, P., Wijesinghe, M., Williams, M., Wilson, L., Cole, S., Winchester, S., Wiselka, M., Wolverson, A., Wootton, D.G., Workman, A., Yates, B., Young, P., 2022. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467-484.

    18. Desingu, P.A., Nagarajan, K., Dhama, K., 2022. Emergence of Omicron third lineage BA.3 and its importance. J. Med. Virol. 94, 1808-1810.

    19. Gao, L., Zhou, J., Yang, S., Wang, L., Chen, X., Yang, Y., Li, R., Pan, Z., Zhao, J., Li, Z., Huang, Q., Tang, J., Hu, L., Liu, P., Zhang, G., Chen, Y., Ye, L., 2021. The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity. Signal Transduct. Targeted Ther. 6, 113.

    20. Garcia-Beltran, W.F., St Denis, K.J., Hoelzemer, A., Lam, E.C., Nitido, A.D., Sheehan, M.L., Berrios, C., Ofoman, O., Chang, C.C., Hauser, B.M., Feldman, J., Roederer, A.L., Gregory, D.J., Poznansky, M.C., Schmidt, A.G., Iafrate, A.J., Naranbhai, V., Balazs, A.B., 2022. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457-466.

    21. GeurtsvanKessel, C.H., Geers, D., Schmitz, K.S., Mykytyn, A.Z., Lamers, M.M., Bogers, S., Scherbeijn, S., Gommers, L., Sablerolles, R.S.G., Nieuwkoop, N.N., Rijsbergen, L.C., van Dijk, L.L.A., de Wilde, J., Alblas, K., Breugem, T.I., Rijnders, B.J.A., de Jager, H., Weiskopf, D., van der Kuy, P.H.M., Sette, A., Koopmans, M.P.G., Grifoni, A., Haagmans, B.L., de Vries, R.D., 2022. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Science Immunology 7, o2202.

    22. Goel, R.R., Painter, M.M., Lundgreen, K.A., Apostolidis, S.A., Baxter, A.E., Giles, J.R., Mathew, D., Pattekar, A., Reynaldi, A., Khoury, D.S., Gouma, S., Hicks, P., Dysinger, S., Hicks, A., Sharma, H., Herring, S., Korte, S., Kc, W., Oldridge, D.A., Erickson, R.I., Weirick, M.E., McAllister, C.M., Awofolaju, M., Tanenbaum, N., Dougherty, J., Long, S., D Andrea, K., Hamilton, J.T., McLaughlin, M., Williams, J.C., Adamski, S., Kuthuru, O., Drapeau, E.M., Davenport, M.P., Hensley, S.E., Bates, P., Greenplate, A.R., Wherry, E.J., 2022. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell 185, 1875-1887.

    23. Grabowski, F., Kochańczyk, M., Lipniacki, T., 2022. The spread of SARS-CoV-2 variant omicron with a doubling time of 2.0-3.3 Days can Be explained by immune evasion. Viruses 14, 294.

    24. Halfmann, P.J., Iida, S., Iwatsuki-Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S.M., Darling, T.L., Joshi, A., Loeber, S., Singh, G., Foster, S.L., Ying, B., Case, J.B., Chong, Z., Whitener, B., Moliva, J., Floyd, K., Ujie, M., Nakajima, N., Ito, M., Wright, R., Uraki, R., Warang, P., Gagne, M., Li, R., Sakai-Tagawa, Y., Liu, Y., Larson, D., Osorio, J.E., Hernandez-Ortiz, J.P., Henry, A.R., Ciuoderis, K., Florek, K.R., Patel, M., Odle, A., Wong, L.R., Bateman, A.C., Wang, Z., Edara, V., Chong, Z., Franks, J., Jeevan, T., Fabrizio, T., DeBeauchamp, J., Kercher, L., Seiler, P., Gonzalez-Reiche, A.S., Sordillo, E.M., Chang, L.A., van Bakel, H., Simon, V., Alburquerque, B., Alshammary, H., Amoako, A.A., Aslam, S., Banu, R., Cognigni, C., Espinoza-Moraga, M., Farrugia, K., van de Guchte, A., Khalil, Z., Laporte, M., Mena, I., Paniz-Mondolfi, A.E., Polanco, J., Rooker, A., Sominsky, L.A., Douek, D.C., Sullivan, N.J., Thackray, L.B., Ueki, H., Yamayoshi, S., Imai, M., Perlman, S., Webby, R.J., Seder, R.A., Suthar, M.S., García-Sastre, A., Schotsaert, M., Suzuki, T., Boon, A.C.M., Diamond, M.S., Kawaoka, Y., 2022. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687-692.

    25. Harvey, W.T., Carabelli, A.M., Jackson, B., Gupta, R.K., Thomson, E.C., Harrison, E.M., Ludden, C., Reeve, R., Rambaut, A., Peacock, S.J., Robertson, D.L., 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409-424.

    26. He, G., Zhu, S., Fu, D., Xiao, J., Zhao, J., Lin, Z., Liu, T., Liang, X., Ma, W., 2022. SingaporeAssociation between COVID-19 Vaccination Coverage and Case Fatality Ratio:a Comparative Study - Hong Kong SAR, China and Singapore, December 2021-March 2022. China CDC Wkly 4, 649-654.

    27. Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A., Winkler, M.S., Lier, M., Dopfer-Jablonka, A., Jäck, H., Behrens, G.M.N., Pöhlmann, S., 2022. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell 185, 447-456.

    28. Iketani, S., Liu, L., Guo, Y., Liu, L., Chan, J.F.W., Huang, Y., Wang, M., Luo, Y., Yu, J., Chu, H., Chik, K.K.H., Yuen, T.T.T., Yin, M.T., Sobieszczyk, M.E., Huang, Y., Yuen, K., Wang, H.H., Sheng, Z., Ho, D.D., 2022. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553-556.

    29. Keeton, R., Tincho, M.B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S., Bernstein, M., Karim, F., Madzorera, S.V., Moyo-Gwete, T., Mennen, M., Skelem, S., Adriaanse, M., Mutithu, D., Aremu, O., Stek, C., du Bruyn, E., Van Der Mescht, M.A., de Beer, Z., de Villiers, T.R., Bodenstein, A., van den Berg, G., Mendes, A., Strydom, A., Venter, M., Giandhari, J., Naidoo, Y., Pillay, S., Tegally, H., Grifoni, A., Weiskopf, D., Sette, A., Wilkinson, R.J., de Oliveira, T., Bekker, L., Gray, G., Ueckermann, V., Rossouw, T., Boswell, M.T., Bhiman, J.N., Moore, P.L., Sigal, A., Ntusi, N.A.B., Burgers, W.A., Riou, C., 2022. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488-492.

    30. Khan, K., Karim, F., Ganga, Y., Bernstein, M., Jule, Z., Reedoy, K., Cele, S., Lustig, G., Amoako, D., Wolter, N., Samsunder, N., Sivro, A., San, J.E., Giandhari, J., Tegally, H., Pillay, S., Naidoo, Y., Mazibuko, M., Miya, Y., Ngcobo, N., Manickchund, N., Magula, N., Karim, Q.A., von Gottberg, A., Abdool, K.S., Hanekom, W., Gosnell, B.I., Lessells, R.J., de Oliveira, T., Moosa, M.S., Sigal, A., 2022. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat. Commun. 13, 4686.

    31. Kim, W., Zhou, J.Q., Horvath, S.C., Schmitz, A.J., Sturtz, A.J., Lei, T., Liu, Z., Kalaidina, E., Thapa, M., Alsoussi, W.B., Haile, A., Klebert, M.K., Suessen, T., Parra-Rodriguez, L., Mudd, P.A., Whelan, S.P.J., Middleton, W.D., Teefey, S.A., Pusic, I., O Halloran, J.A., Presti, R.M., Turner, J.S., Ellebedy, A.H., 2022. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141-145.

    32. Kimura, I., Yamasoba, D., Tamura, T., Nao, N., Oda, Y., Mitoma, S., Ito, J., Nasser, H., Zahradnik, J., Uriu, K., Fujita, S., Kosugi, Y., Wang, L., Tsuda, M., Kishimoto, M., Ito, H., Suzuki, R., Shimizu, R., Begum, M.M., Yoshimatsu, K., Sasaki, J., SasakiTabata, K., Yamamoto, Y., Nagamoto, T., Kanamune, J., Kobiyama, K., Asakura, H., Nagashima, M., Sadamasu, K., Yoshimura, K., Kuramochi, J., Schreiber, G., Ishii, K.J., Hashiguchi, T., Ikeda, T., Saito, A., Fukuhara, T., Tanaka, S., Matsuno, K., Sato, K., 2022. Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA. subvariants, including BA.4 and BA.5. Cell 185, 3992-4007.e16.

    33. Kotaki, R., Adachi, Y., Moriyama, S., Onodera, T., Fukushi, S., Nagakura, T., Tonouchi, K., Terahara, K., Sun, L., Takano, T., Nishiyama, A., Shinkai, M., Oba, K., NakamuraUchiyama, F., Shimizu, H., Suzuki, T., Matsumura, T., Isogawa, M., Takahashi, Y., 2022. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine. Science Immunology 7, n8590.

    34. Kumar, S., Thambiraja, T.S., Karuppanan, K., Subramaniam, G., 2022. Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein. J. Med. Virol. 94, 1641-1649.

    35. Lambrou, A.S., Shirk, P., Steele, M.K., Paul, P., Paden, C.R., Cadwell, B., Reese, H.E., Aoki, Y., Hassell, N., Zheng, X., Talarico, S., Chen, J.C., Oberste, M.S., Batra, D., McMullan, L.K., Halpin, A.L., Galloway, S.E., MacCannell, D.R., Kondor, R., Barnes, J., MacNeil, A., Silk, B.J., Dugan, V.G., Scobie, H.M., Wentworth, D.E., 2022.

    36. Genomic surveillance for SARS-CoV-2 variants: predominance of the delta(B.1.617.2) and omicron (B.1.1.529) variants — United States, june 2021-january 2022. MMWR. Morbidity and Mortality Weekly Report 71, 206-211.

    37. Lewnard, J.A., Hong, V.X., Patel, M.M., Kahn, R., Lipsitch, M., Tartof, S.Y., 2022. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California. Nat. Med. 28, 1933-1943.

    38. Liu, Y., Röcklov, J., 2022. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J. Trav. Med. 29, taac037.

    39. Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M., McMahan, K., Sciacca, M., VanWyk, H., Wu, C., Yu, J., Collier, A.Y., Barouch, D.H., 2022a. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature 603, 493-496.

    40. Liu, L., Iketani, S., Guo, Y., Chan, J.F.W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M.S., Yu, J., Chik, K.K.H., Yuen, T.T.T., Yoon, C., To, K.K.W., Chen, H., Yin, M.T., Sobieszczyk, M.E., Huang, Y., Wang, H.H., Sheng, Z., Yuen, K., Ho, D.D., 2022b. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.

    41. Nature 602, 676-681.

    42. Lu, L., Mok, B.W., Chen, L., Chan, J.M., Tsang, O.T., Lam, B.H., Chuang, V.W., Chu, A.W., Chan, W., Ip, J.D., Chan, B.P., Zhang, R., Yip, C.C., Cheng, V.C., Chan, K., Jin, D., Hung, I.F., Yuen, K., Chen, H., To, K.K., 2021. Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients. Clin. Infect. Dis. 75, e822-e826.

    43. Lusvarghi, S., Pollett, S.D., Neerukonda, S.N., Wang, W., Wang, R., Vassell, R., Epsi, N.J., Fries, A.C., Agan, B.K., Lindholm, D.A., Colombo, C.J., Mody, R., Ewers, E.C., Lalani, T., Ganesan, A., Goguet, E., Hollis-Perry, M., Coggins, S., Simons, M.P., Katzelnick, L.C., Wang, G., Tribble, D.R., Bentley, L., Eakin, A.E., Broder, C.C., Erlandson, K.J., Laing, E.D., Burgess, T.H., Mitre, E., Weiss, C.D., 2021. SARS-CoV-2 Omicron Neutralization by Therapeutic Antibodies, Convalescent Sera, and PostmRNA Vaccine Booster. bioRxiv, 2021.12.22.473880.

    44. Lyke, K.E., Atmar, R.L., Islas, C.D., Posavad, C.M., Szydlo, D., Paul, C.R., Deming, M.E., Eaton, A., Jackson, L.A., Branche, A.R., El, S.H., Rostad, C.A., Martin, J.M., Johnston, C., Rupp, R.E., Mulligan, M.J., Brady, R.C., Frenck, R.J., Backer, M., Kottkamp, A.C., Babu, T.M., Rajakumar, K., Edupuganti, S., Dobrzynski, D., Coler, R.N., Archer, J.I., Crandon, S., Zemanek, J.A., Brown, E.R., Neuzil, K.M., Stephens, D.S., Post, D.J., Nayak, S.U., Suthar, M.S., Roberts, P.C., Beigel, J.H., Montefiori, D.C., 2022. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med 3, 100679.

    45. Ma, C., Chen, X., Mei, F., Xiong, Q., Liu, Q., Dong, L., Liu, C., Zou, W., Zhan, F., Hu, B., Liu, Y., Liu, F., Zhou, L., Xu, J., Jiang, Y., Xu, K., Cai, K., Chen, Y., Yan, H., Lan, K., 2022. Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents. Emerg. Microb. Infect. 11, 567-572.

    46. Mannar, D., Saville, J.W., Zhu, X., Srivastava, S.S., Berezuk, A.M., Tuttle, K.S., Marquez, A.C., Sekirov, I., Subramaniam, S., 2022. SARS-CoV-2 Omicron variant:antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science 375, 760-764.

    47. Mazzoni, A., Vanni, A., Spinicci, M., Capone, M., Lamacchia, G., Salvati, L., Coppi, M., Antonelli, A., Carnasciali, A., Farahvachi, P., Giovacchini, N., Aiezza, N., Malentacchi, F., Zammarchi, L., Liotta, F., Rossolini, G.M., Bartoloni, A., Cosmi, L., Maggi, L., Annunziato, F., 2022. SARS-CoV-2 spike-specific CD4+ T cell response is conserved against variants of concern, including omicron. Front. Immunol. 13, 801431.

    48. McCallum, M., Czudnochowski, N., Rosen, L.E., Zepeda, S.K., Bowen, J.E., Walls, A.C., Hauser, K., Joshi, A., Stewart, C., Dillen, J.R., Powell, A.E., Croll, T.I., Nix, J., Virgin, H.W., Corti, D., Snell, G., Veesler, D., 2022. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science 375, 864-868.

    49. Meng, B., Abdullahi, A., Ferreira, I.A.T.M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P.P., Fatihi, S., Rathore, S., Zepeda, S.K., Papa, G., Kemp, S.A., Ikeda, T., Toyoda, M., Tan, T.S., Kuramochi, J., Mitsunaga, S., Ueno, T., Shirakawa, K., Takaori-Kondo, A., Brevini, T., Mallery, D.L., Charles, O.J., Baker, S., Dougan, G., Hess, C., Kingston, N., Lehner, P.J., Lyons, P.A., Matheson, N.J., Ouwehand, W.H., Saunders, C., Summers, C., Thaventhiran, J.E.D., Toshner, M., Weekes, M.P., Maxwell, P., Shaw, A., Bucke, A., Calder, J., Canna, L., Domingo, J., Elmer, A., Fuller, S., Harris, J., Hewitt, S., Kennet, J., Jose, S., Kourampa, J., Meadows, A., O Brien, C., Price, J., Publico, C., Rastall, R., Ribeiro, C., Rowlands, J., Ruffolo, V., Tordesillas, H., Bullman, B., Dunmore, B.J., Gräf, S., Hodgson, J., Huang, C., Hunter, K., Jones, E., Legchenko, E., Matara, C., Martin, J., Mescia, F., O Donnell, C., Pointon, L., Shih, J., Sutcliffe, R., Tilly, T., Treacy, C., Tong, Z., Wood, J., Wylot, M., Betancourt, A., Bower, G., Cossetti, C., De Sa, A., Epping, M., Fawke, S., Gleadall, N., Grenfell, R., Hinch, A., Jackson, S., Jarvis, I., Krishna, B., Nice, F., Omarjee, O., Perera, M., Potts, M., Richoz, N., Romashova, V., Stefanucci, L., Strezlecki, M., Turner, L., De Bie, E.M.D.D., Bunclark, K., Josipovic, M., Mackay, M., Butcher, H., Caputo, D., Chandler, M., Chinnery, P., Clapham-Riley, D., Dewhurst, E., Fernandez, C., Furlong, A., Graves, B., Gray, J., Hein, S., Ivers, T., Le Gresley, E., Linger, R., Kasanicki, M., King, R., Kingston, N., Meloy, S., Moulton, A., Muldoon, F., Ovington, N., Papadia, S., Penkett, C.J., Phelan, I., Ranganath, V., Paraschiv, R., Sage, A., Sambrook, J., Scholtes, I., Schon, K., Stark, H., Stirrups, K.E., Townsend, P., Walker, N., Webster, J., Butlertanaka, E.P., Tanaka, Y.L., Ito, J., Uriu, K., Kosugi, Y., Suganami, M., Oide, A., Yokoyama, M., Chiba, M., Motozono, C., Nasser, H.,Shimizu, R., Kitazato, K., Hasebe, H., Irie, T., Nakagawa, S., Wu, J., Takahashi, M., Fukuhara, T., Shimizu, K., Tsushima, K., Kubo, H., Kazuma, Y., Nomura, R., Horisawa, Y., Nagata, K., Kawai, Y., Yanagida, Y., Tashiro, Y., Tokunaga, K., Ozono, S., Kawabata, R., Morizako, N., Sadamasu, K., Asakura, H., Nagashima, M., Yoshimura, K., Cárdenas, P., Muñoz, E., Barragan, V., Márquez, S., Prado-Vivar, B., Becerra-Wong, M., Caravajal, M., Trueba, G., Rojas-Silva, P., Grunauer, M., Gutierrez, B., Guadalupe, J.J., Fernández-Cadena, J.C., Andrade-Molina, D., Baldeon, M., Pinos, A., Bowen, J.E., Joshi, A., Walls, A.C., Jackson, L., Martin, D., Smith, K.G.C., Bradley, J., Briggs, J.A.G., Choi, J., Madissoon, E., Meyer, K.B., Mlcochova, P., Ceron-Gutierrez, L., Doffinger, R., Teichmann, S.A., Fisher, A.J., Pizzuto, M.S., de Marco, A., Corti, D., Hosmillo, M., Lee, J.H., James, L.C., Thukral, L., Veesler, D., Sigal, A., Sampaziotis, F., Goodfellow, I.G., Matheson, N.J., Sato, K., Gupta, R.K., 2022. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706-714.

    50. Meo, S.A., Meo, A.S., Al-Jassir, F.F., Klonoff, D.C., 2021. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur. Rev. Med. Pharmacol. Sci. 25, 8012-8018.

    51. Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Ben Tanfous, T., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., Raspe, R., Schaefer-Babajew, D., Shimeliovich, I., Daga, M., Yao, K., Schmidt, F., Millard, K.G., Turroja, M., Jankovic, M., Oliveira, T.Y., Gazumyan, A., Caskey, M., Hatziioannou, T., Bieniasz, P.D., Nussenzweig, M.C., 2022. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature 607, 128-134.

    52. Muik, A., Lui, B.G., Wallisch, A., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Güimil Garcia, R.D.L.C., Poran, A., Shpyro, S., Finlayson, A., Cai, H., Yang, Q., Swanson, K.A., Türeci, Ö., Şahin, U., 2022. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678-680.

    53. Naranbhai, V., Nathan, A., Kaseke, C., Berrios, C., Khatri, A., Choi, S., Getz, M.A., TanoMenka, R., Ofoman, O., Gayton, A., Senjobe, F., Zhao, Z., St Denis, K.J., Lam, E.C., Carrington, M., Garcia-Beltran, W.F., Balazs, A.B., Walker, B.D., Iafrate, A.J., Gaiha, G.D., 2022. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell 185, 1041-1051.

    54. Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C., Kreiss, Y., Alroy-Preis, S., Regev-Yochay, G., Mendelson, E., Mandelboim, M., 2022. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N. Engl. J. Med. 386, 492-494.

    55. Nishiura, H., Ito, K., Anzai, A., Kobayashi, T., Piantham, C., Rodríguez-Morales, A.J., 2022. Relative reproduction number of SARS-CoV-2 omicron (B.1.1.529) compared with delta variant in South Africa. J. Clin. Med. 11, 30.

    56. Nordstrom, P., Ballin, M., Nordstrom, A., 2022. Effectiveness of a Fourth Dose of mRNA COVID-19 Vaccine against All-Cause Mortality in Long-Term Care Facility Residents and in the Oldest Old: A Nationwide, Retrospective Cohort Study in Sweden. Lancet Reg Health Eur. 21, 100466.

    57. Nyberg, T., Ferguson, N.M., Nash, S.G., Webster, H.H., Flaxman, S., Andrews, N., Hinsley, W., Bernal, J.L., Kall, M., Bhatt, S., Blomquist, P., Zaidi, A., Volz, E., Aziz, N.A., Harman, K., Funk, S., Abbott, S., Hope, R., Charlett, A., Chand, M., Ghani, A.C., Seaman, S.R., Dabrera, G., De Angelis, D., Presanis, A.M., Thelwall, S., Nyberg, T., Ferguson, N.M., Nash, S.G., Webster, H.H., Flaxman, S., Andrews, N., Hinsley, W., Lopez Bernal, J., Kall, M., Bhatt, S., Blomquist, P., Zaidi, A., Volz, E., Abdul Aziz, N., Harman, K., Funk, S., Abbott, S., Hope, R., Charlett, A., Chand, M., Ghani, A.C., Seaman, S.R., Dabrera, G., De Angelis, D., Presanis, A.M., Thelwall, S., 2022. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 399, 1303-1312.

    58. Obermeyer, F., Jankowiak, M., Barkas, N., Schaffner, S.F., Pyle, J.D., Yurkovetskiy, L., Bosso, M., Park, D.J., Babadi, M., MacInnis, B.L., Luban, J., Sabeti, P.C., Lemieux, J.E., 2022. Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. Science 376, 1327-1332.

  • 加载中

Article Metrics

Article views(312) PDF downloads(1) Cited by()

Related
Proportional views
    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages

      Corresponding author: Xin Zheng, xinz@hust.edu.cn
    • a Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China;
    • b Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan 430022, China

    Abstract: The recently discovered SARS-CoV-2 variant Omicron (B.1.1.529) has rapidly become a global public health issue. The substantial mutations in the spike protein in this new variant have raised concerns about its ability to escape from pre-existing immunity established by natural infection or vaccination. In this review, we give a summary of current knowledge concerning the antibody evasion properties of Omicron and its subvariants (BA.2, BA.2.12.1, BA.4/5, and BA.2.75) from therapeutic monoclonal antibodies and the sera of SARS-CoV-2 vaccine recipients or convalescent patients. We also summarize whether vaccine-induced cellular immunity (memory B cell and T cell response) can recognize Omicron specifically. In brief, the Omicron variants demonstrated remarkable antibody evasion, with even more striking antibody escape seen in the Omicron BA.4 and BA.5 sub-lineages. Luckily, the third booster vaccine dose significantly increased the neutralizing antibodies titers, and the vaccine-induced cellular response remains conserved and provides second-line defense against the Omicron.

    Reference (58) Relative (20)

    目录

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return